RMi pre-open: Slow Walk

October 28, 2025 8:06am

I’m getting on my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

Expect earnings’ results that meet, beat or miss revenue estimates, expectations, consensus … sector earnings while LPS (loss-per-share) assumes adjustments

Pre-open Signals: 1 Positive, 4 Negative Indications and lots of drops from aftermarket to pre-open

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

Short on words, long on being judiciously predictive!

Monday night’s … RMi Closing Bell: Skidding … https://www.regmedinvestors.com/articles/14169   

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Tuesday: The pre-open Dow futures are UP +0.36% or (+172 points), the S&P futures are up +0.07% or (+4.75 points) and the Nasdaq futures are UP +0.13% or (+33 points)

• Stock futures are up and inching, Tuesday 10/28
• European markets turned negative,
• Asia Pacific markets mostly declined.

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Monday: The Dow closed UP +337.47 points or +0.71%, the S&P closed UP +83.47 points or +1.23% while the Nasdaq closed UP +432.589 points or +1.86%
• Friday: The Dow closed UP +472.51 points or +1.01%, the S&P closed UP +53.29 points or +0.79% while the Nasdaq closed UP +263.069 points or +1.15%
• Last week: the S&P 500 is up +2%, the Dow +2% and the Nasdaq added +2%.
• The previous week: the S&P 500 was up +1.7%, the Dow +1.6% and the Nasdaq +2.1%.
• Last month and Q3’s numbers, the S&P 500 Q was up +7% and the month -4.2%, the Nasdaq’s Q is up +11% and the month +5% while the Dow’s Q is up +5% and the month +1%

Economic Data Docket: S&P Case-Shiller home price index (20 cities) - Aug., 10:00 am      Consumer confidence

Q4 – 1 neutral, 9 positive and 9 negative closes

• Q3 – September, 1 holiday, 9 negative and 12 positive closes; August - 11 negative and 9 positive closes; July – 1 market holiday, 13 positive and 9 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• October began with a government shutdown and much fewer econs… along with the usual ups, downs
• Now uncertainty rules

Info:

uniQure NV (QURE) closed up +$6.91 after Friday’s +$1.68 with a negative -$0.72 or -1.06% pre-open

CRISPR Therapeutics (CRSP) closed down -$1.89 with a negative -$0.27 or -0.41% pre-open

Beam Therapeutics (BEAM) closed down -$1.23 after Friday’s -$0.24 with a negative -$0.54 or -2.02% pre-open

Vertex (VRTX) closed down -$1.22 after Friday’s +$1.24 with a negative -$0.54 or -0.14% pre-open

Lenz Therapeutics (LENZ) closed down -$0.68 after Friday’s +$0.59 with a positive +$0.66 or +2.11% pre-open

The BOTTOM LINE: I’m getting on my horse with a lantern as I ride yelling … “earnings are here, earnings are here”!

Q3 Earnings are in the front-view mirror this week progressing into November …!

• On Tuesday 10/28; MiMedx (MDXG) Ionis Pharmaceuticals IONS), AxoGen (AXGN) on 10/29 with Sarepta Therapeutics (SUPN) on 11/3, Supernus Therapeutics (SUPN) on 11/4 followed by Moderna (MRNA) and Vericel (VCEL) on 11/6 with Moderna (MRNA) on 11/6

Earnings: IQVIA (NYSE: IQV) The clinical testing company reporting earnings today …

• IQV reported Q3 profit of $331 million,
• IQV had net income of $1.93 per share,
• Earnings, adjusted for one-time gains and costs, came to $3 per share surpassing expectations,
• The average estimate of nine analysts surveyed by Zacks was for earnings of $2.96 per share,
• Posted revenue of $4.1 billion in the period, also beating “street” forecasts,
• 8 analysts surveyed by Zacks expected $4.07 billion,
• IQVIA expects full-year earnings in the range of $11.85 to $11.95 per share, with revenue in the range of $16.15 billion to $16.25 billion,

• Pre-report Q3 estimate was for revenue to grow 4.7% year on year to $4.08 billion, in line with the 4.3% increase it recorded in Q3/24. Adjusted earnings are expected to come in at $2.98 per share.

Bad news, not so bad or no news … in the coming week is a reason to consider adding or subtract as needed to “portfolio exposure” as proximity to earnings release come to appear …

• If the Fed meeting and trade talks are positive catalysts, investors will want to get more aggressive.
• As sector earnings meet, beat or miss expectations; whipsaw actions could ensue depreciations or the stock market heads south, back pedal -- fast.

The shutdown enters its 28^th day today, with lawmakers still unable to agree on a funding bill … as Democrats block the 12th negotiation

Welcome to my world of defining the “grey’ in our universe!

• “I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

October: understand the new “flow” …

New week:

• 10/27- Monday closed negative with 18 positive, 22 negative and 0 flats

Last week:

• 10/24 - Friday closed positive with 25 positive, 13 negative and 2 flats
• 10/23 – Thursday closed negative with 15 negative, 22 negative and 3 flats
• 10/22 – Wednesday closed negative with 4 positive, 34 negative and 2 flat
• 10/21 - Tuesday closed negative with 17 positive, 23 negative and 0 flat
• 10/20 - Monday closed positive with 34 positive, 4 negative and 2 flats

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.